Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor

Journal of Immunology

Volumn 180, Issue 12, 2008, Pages 7989-8003

  Podolin, Patricia L ^a   Bolognese, Brian J ^a   Carpenter, Donald C ^a   Davis, T Gregg ^a   Johanson, Roy A ^a,d   Fox, Josephine H ^a,e   Long III, Edward ^a   Dong, Xiaoyang ^c   Marquis, Robert W ^c   LoCastro, Stephen M ^c   Terfloth, Gerald J ^a   Kurali, Edit ^b   Peterson, John J ^a   Smith, Brian R ^a,e   McQueney, Michael S ^a   Yamashita, Dennis S ^c   Capper Spudich, Elizabeth A ^a,f  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Microbial Musculoskel P   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN; CYSTEINE PROTEINASE INHIBITOR; INTERLEUKIN 1BETA; MYELIN BASIC PROTEIN; SB 33170; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 5 (2 MORPHOLIN 4 YLETHOXY)BENZOFURAN 2 CARBOXYLIC ACID (3 METHYL 1 (3 OXO 1 (2 (3 PYRIDIN 2 YLPHENYL)ACETYL)AZEPAN 4 YLCARBAMOYL)BUTYL)AMIDE; 5-(2-MORPHOLIN-4-YLETHOXY)BENZOFURAN-2-CARBOXYLIC ACID (3-METHYL-1-(3-OXO-1-(2-(3-PYRIDIN-2-YLPHENYL)ACETYL)AZEPAN-4-YLCARBAMOYL)BUTYL)AMIDE; AZEPINE DERIVATIVE; B LYMPHOCYTE ANTIGEN; BENZOFURAN DERIVATIVE; CATHEPSIN; COLLAGEN TYPE 2; DRUG DERIVATIVE; HLA ANTIGEN CLASS 2; LEUCINE; PYRIDINE DERIVATIVE; SB 331750;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; SPLEEN CELL; ANIMAL; C57BL MOUSE; CATTLE; CELL CULTURE; CYTOLOGY; DBA MOUSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOLOGY; INVARIANT CHAIN; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MOUSE MUTANT; PROTEIN PROCESSING; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ARTHRITIS, EXPERIMENTAL; AZEPINES; BENZOFURANS; CATHEPSINS; CATTLE; CELL LINE, TUMOR; CELLS, CULTURED; COLLAGEN TYPE II; CYSTEINE PROTEINASE INHIBITORS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUCINE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIDINES; SPLEEN;

EID: 50949122918     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.12.7989     Document Type: Article

References (65)

1. Schwartz, R. H. 1985. T-lymphocyte recognition of antigen in association with gene products of the major hislocompatibilily complex. Annu. Rev. Immunol. 3: 237-261.
2. Bryant, P. W., A. M. Lennon-Dumenil, E. Fiebiger, C. Lagaudrierc-Gesbert, and H. L. Ploegh. 2002. Proteolysis and antigen presentation by MHC class II molecules. Adv. Immunol. 80: 71-114.
3. Honey, K., and A. Y. Rudensky. 2003. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3: 472-482.
4. Watts, C. 2004. The exogenous pathway for antigen presentation on major his-tocompatibility complex class II and CD1 molecules. Nat. Immunol. 5: 685-692.
5. Denzin, L. K., C. Hammond, and P. Cresswell. 1996. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. hied. 184: 2153-2165.
6. Riese, R. J., R. N. Mitchell, J. A. Villadangos, G.-P. Shi, J. T. Palmer, E. R. Karp, G. T. De Sanctis, H. L. Ploegh, and H. A. Chapman. 1998. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 101: 2351-2363.
7. Nakagawa, T. Y., W. H. Brissette, P. D. Lira, R. J. Griffiths, N. Petrushova, J. Stock, J. D. McNeish, S. E. Eastman, E. D. Howard, S. R. M. Clarke, et al. 1999. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10: 207-217.
8. Shi, G.-P., J. A. Villadangos, G. Dranoff, C. Small, L. Gu, K. J. Haley, R. Riese, H. L. Ploegh, and H. A. Chapman. 1999. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10: 197-206.
9. Shi, G.-P., R. A. R. Bryant, R. Riese, S. Verhelst, C. Driessen, Z. Li, D. Bromme, H. L. Ploegh, and H. A. Chapman. 2000. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J. Exp. Med. 191: 1177-1185.
10. Nakagawa, T., W. Roth, P. Wong, A. Nelson, A. Farr, J. Deussing, J. A. Villadangos, H. Ploegh, C. Peters, and A. Y. Rudensky. 1998. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 280: 450-453.
11. Tolosa, E., W. Li, Y. Yasuda, W. Wienhold, L. K. Denzin, A. Lautwein, C. Driessen, P. Schnorrer, E. Weber, S. Stevanovic, et al. 2003. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overex-pressed in myasthenia gravis. J. Clin. Invest. 112: 517-526.
12. Bania, J., E. Gatti, H. Lelouard, A. David, F. Cappello, E. Weber, V. Camosseto, and P. Pierre. 2003. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc. Natl. Acad. Sci. USA 100: 6664-6669.
13. Beers, C, A. Burich, M. J. Kleijmeer, J. M. Griffith, P. Wong, and A. Y. Rudensky. 2005. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J. Immunol. 174: 1205-1212.
14. Myers, L. K., E. F. Rosloniec, M. A. Cremer, and A. H. Kang. 1997. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61: 1861-1878.
15. Ranges, G. E., S. Sriram, and S. M. Cooper. 1985. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162: 1105-1110.
16. Latham, K. A., K. B. Whittington, R. Zhou, Z. Qian, and E. F. Rosloniec. 2005. Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J. Immunol. 174: 3978-3985.
17. Wooley, P. H., H. S. Luthra, J. M. Stuart, and C. S. David. 1981. Type II collagen-induced arthritis in mice: I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154: 688-700.
18. Wooley, P. H., H. S. Luthra, M. M. Griffiths, J. M. Stuart, A. Huse, and C. S. David. 1985. Type II collagen-induced arthritis in mice: IV. Variations in immunogenetic regulation provide evidence for multiple arthritogenic epitopes on the collagen molecule. J. Immunol. 135: 2443-2451.
19. Hafler, D. A., and H. L. Weiner. 1995. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144: 75-107.
20. Swanborg, R. H. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77: 4-13.
21. Kuchroo, V. K., and H. L. Weiner. 1998. Antigen-driven regulation of experimental autoimmune encephalomyelitis. Res. Immunol. 149: 759-771.
22. Fritz, R. B., M. J. Skeen, C.-H. Jen Chou, M. Garcia, and I. K. Egorov. 1985. Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. J. Immunol. 134: 2328-2332.
23. Lamont, A. G., A. Sette, R. Fujinami, S. M. Colon, C. Miles, and H. M. Grey. 1990. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules. J. Immunol. 145: 1687-1693:
24. Marquis, R. W., Y. Ru, S. M. LoCastro, J. Zeng, D. S. Yamashita, H.-J. Oh, K. F. Erhard, L. D. Davis, T. A. Tomaszek, D. Tew, et al. 2001. Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. 44: 1380-1395.
25. Palmer, J. T., D. Rasnick, J. L. Klaus, and D. Bromme. 1995. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38: 3193-3196.
26. McGrath, M. E., P. A. Sprengeler, C. M. Hill, V. Martichonok, H. Cheung, J. R. Somoza, J. T. Palmer, and J. W. Janc. 2003. Peptide ketobenzoxazole inhibitors bound to cathepsin K. Biochemistry 42: 15018-15028.
27. Gowen, M., F. Lazner, R. Dodds, R. Kapadia, J. Feild, M. Tavaria, I. Bertoncello, F. Drake, S. Zavarselk, I. Tellis, et al. 1999. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14: 1654-1663.
28. Bromme, D., Z. Li, M. Barnes, and E. Mehler. 1999. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry 38: 2377-2385.
29. +2-T lymphocytes. J. Immunol. 127: 1420-1423.
30. Bernard, C. C. A., T. G. Johns, A. Slavin, M. Ichikawa, C. Ewing, J. Liu, and J. Bettadapura. 1997. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 75: 77-88.
31. Marks, M. S., J. S. Blum, and P. Cresswell. 1990. Invariant chain trimers are sequestered in the rough endoplxsmic reticulum in the absence of association with HLA class II antigens. J. Cell Biol. 111: 839-855.
32. Thornbcrry, N. A., H. G. Bull, J. R. Calaycay, K. T. Chapman, A. D. Howard, M. J. Kostura, D. K. Miller, S. M. Molineaux, J. R. Weidner, J. Aunins, et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356: 768-774.
33. Cerretti, D. P., C. J. Kozlosky, B. Mosley, N. Nelson, K. Van Ness, T. A. Greenstreet, C. J. March, S. R. Kronheim, T. Druck, L. A. Cannizzaro, et al. 1992. Molecular cloning of the interleukin-1β converting enzyme. Science 256: 97-100.
34. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, K. L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells Nature 385: 729-733.
35. Coeshott, C., C. Ohnemus, A. Pilyavskaya, S. Ross, M. Wieczorek, H. Kroona, A. H. Leimer, and J. Cheronis. 1999. Converting enzyme-independent release of tumor necrosis factor-a and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl. Acad Sci. USA 96: 6261-6266.
36. Yang, H., M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, and P. Christadoss. 2005. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J. Immunol. 174: 1729-1737.
37. Biroc, S. L., S. Gay, K. Hummel, C. Magill, J. T. Palmer, D. R. Spencer, S. Sa, J. L. Klaus, B. A. Michel, D. Rasnick, and R. E. Gay. 2001. Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis Rheum. 44: 703-711.
38. Saegusa, K., N. Ishimaru, K. Yanagi, R. Arakaki, K. Ogawa, I. Saito, N. Katunuma, and Y. Hayashi. 2002. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest. 110: 361-369.
39. Sette, A., S. Southwood, J. Miller, and E. Appella. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J. Exp. Med. 181: 677-683.
40. Avva, R. R., and P. Cresswell. 1994. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1: 763-774.
41. Villadangos, J. A., R. J. Riese, C. Peters, H. A. Chapman, and H. L. Ploegh. 1997. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med. 186: 549-560.
42. Patil, N. S., A. Pashine, M. P. Belmares, W. Liu, B. Kaneshiro, J. Rabinowitz, H. McConnell, and E. D. Mellins. 2001. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles. J. Immunol. 167: 7157-7168.
43. Buckner, J., W. W. Kwok, B. Nepon, and G. T. Nepom. 1996. Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions. J. Immunol. 157: 4940-4945.
44. Hausmann, D. H. F., B. Yu, S. Hausmann, and K. W. Wucherpfennig. 1999. pH-dependent peptide binding properties of the type 1 diabetes-associated I-As7 molecule: rapid release of CLIP at an endosomal pH. J. Exp. Med. 189: 1723-1733.
45. *0201) molecule. Eur. J. Immunol. 26: 2764-2772.
46. Honey, K., K. Forbush, P. E. Jensen, and A. Y. Rudensky. 2004. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M. J. Immunol. 172: 4142-4150.
47. Neefjes, J. J., and H. L. Ploegh. 1992. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistant α β heterodimers in endosomes. EMBO J. 11: 411-416.
48. Loss, G. E., and A. J. Sant. 1993. Invariant chain retains MHC class II molecules in the endocytic pathway. J. Immunol. 150: 3187-3197.
49. Castellino, F., R. Han, and R. N. Germain. 2001. The transmembrane segment of invariant chain mediates binding to MHC class II molecules in a CLIP-indepen-dent manner. Eur. J. Immunol. 31: 841-850.
50. Hsieh, C.-S., P. deRoos, K. Honey, C. Beers, and A. Y. Rudensky. 2002. A role for cathepsin L and cathepsin S in peptide generation of MHC class II presentation. J. Immunol. 168: 2618-2625.
51. Plüger, E. B. E., M. Boes, C. Alfonso, C. J. Schröter, H. Kalbacher, H. L. Ploegh, and C. Driessen. 2002. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur. J. Immunol. 32: 467-476.
52. Kirschke, H., B. Wiederanders, D. Brömme, and A. Rinne. 1989. Cathepsin S from bovine spleen. Biochem. J. 264: 467-473.
53. Beck, H., G. Schwartz, C. J. Schröter, M. Deeg, D. Baier, S. Stevanovic, E. Weber, C. Driessen, and H. Kalbacher. 2001. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur. J. Immunol. 31: 3726-3736.
54. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
55. Ma, Y., and R. M. Pope. 2005. The role of macrophages in rheumatoid arthritis. Curr. Pharm. Des. 11: 569-580.
56. Dinarello, C. A. 1996. Biological basis for interleukin-1 in disease. Blood 87: 2095-2147.
57. Aggarwal, B. B., A. Samanta, and M. Feldmann. 2001. TNFα. In Cytokine Reference. J. J. Oppcnheim and M. Feldmann, eds. Academic Press, San Diego, pp. 413-434.
58. Slavin, A. J., J. M. Soos, O. Stuve, J. C. Patarroyo, H. L. Weiner, A. Fontana, E. K. Bikoff, and S. S. Zamvil. 2001. Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoim-munity. J. Clin. Invest. 108: 1133-1139.
59. Tompkins, S. M., J. Padilla, M. C. Dal Canto, J. P. Y. Ting, L. Van Kaer, and S. D. Miller. 2002. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168: 4173-4183.
60. Santambrogio, L., S. L. Belyanskaya, F. R. Fischer, B. Cipriani, C. F. Brosnan, P. Ricciardi-Castagnoli, L. J. Stem, J. L. Strominger, and R. Riese. 2001. Developmental plasticity of CNS microglia. Proc. Natl. Acad. Sci. USA 98: 6295-6300.
61. Gresser, O., E. Weber, A. Hellwig, S. Riese, and A. Régnier- Vigouroux. 2001. Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S. Eur. J. Immunol. 31: 1813-1824.
62. Matsumoto, Y., K. Ohmori, and M. Fujiwara. 1992. Immune regulation by brain cells in the central nervous system: microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 76: 209-216.
63. Williams, K. C, N. P. Dooley, E. Ulvestad, A. Waage, M. Blain, V. W. Yong, and J. P. Antel. 1995. Antigen presentation by human fetal astrocytes with the cooperative effect of microglia or the microglial-derived cytokine IL-1. J. Neurosci. 15: 1869-1878.
64. Nikcevich, K. M., K. B. Gordon, L. Tan, S. D. Hurst, J. Kroepfl, M. Gardinier, T. A. Barrett, and S. D. Miller. 1997. IFN-γ-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J. Immunol. 158: 614-621.
65. Aloisi, F., F. Ria, G. Penna, and L. Adorini. 1998. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J. Immunol. 160: 4671-4680.